

Fig. 1A

2/9



Fig. 1B





Fig. 1C






Fig. 2B



Fig. 2C

PD	HD	A/B	C	D	E/F										
PAX8 DNA BINDING DOMAINS		PPAR γ NUCLEAR RECEPTOR DOMAINS													
↓															
PAX8e7-PPAR γ el:		AGA	CCT	ACC	CCG	TGG	TGG	CAG	--	AAA	TGA	CCA	TGG	TTG	A
PAX8e8-PPAR γ el:		CGG	GCC	AGG	CCC	TCC	TCT	CAG	--	AAA	TGA	CCA	TGG	TTG	A
PAX8e9-PPAR γ el:		CCA	TCG	CAG	GCA	TGG	TGG	CAG	--	AAA	TGA	CCA	TGG	TTG	A

Fig. 3A

6/9




Fig. 3B




Fig. 3C




Fig. 4A




anti-PPAR γ anti-PPAR γ
+PPAR γ peptide

Fig. 4B


THYROID NEOPLASM	RT-PCR	IMH
Follicular Carcinoma	5/8	7/8
Follicular Adenoma	0/20	0/20
Papillary Carcinoma	0/10	0/10
Multi-nodular Hyperplasia	0/10	0/10

Fig. 4C

THYROID FOLLICULAR CARCINOMA: t(2;3)(q13;p25)--->PAX8-PPAR γ



ACUTE PROMYELOCYTIC LEUKEMIA: t(15;17)(q22;q11-21)--->PML-RAR α



ALVEOLAR RHABDOMYOSARCOMA: t(2;13)(q35;q14)--->PAX3-FKHR




Fig. 5




Fig. 6A




Fig. 6B